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Background: Neck pain is a common symptom in most patients suffering from cervical radiculopathy. However,
some conservative treatments are limited by their modest effectiveness. On the other hand, surgical intervention for
cervical disc disorders is indicated when symptoms are refractory to conservative treatments and neurological
symptoms are progressive. Many patients use complementary and alternative medicine, including traditional
Chinese medicine, to address their symptoms. The purpose of the present study is to examine the efficacy and
safety of Qishe Pill, a compound traditional Chinese herbal medicine, for neck pain in patients with cervical
radiculopathy.
Methods/design: A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and
safety of the Qishe Pill is proposed. The study will include 240 patients from five sites across China and diagnosed
with cervical radiculopathy, according to the following inclusion criteria: age 18 to 65 with pain or stiffness in the
neck for at least 2 weeks (neck disability index score 25 or more) and accompanying arm pain that radiates distally
from the elbow. Qualified participants will be randomly allocated into two groups: Qishe Pill group and placebo
group. The prescription of the trial medications (Qishe Pill/placebo) are 3.75 g each twice a day for 28 consecutive
days. The primary outcome is pain severity. Secondary outcomes are functional status, patient satisfaction, and
adverse events as reported in the trial.
Discussion: Qishe Pill is composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix
Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus. According to modern research and preparation
standards, Qishe Pill is developed to improve on the various symptoms of cervical radiculopathy, especially for neck
pain. As it has a potential benefit in treating patients with neck pain, we designed a double-blind, prospective,
randomized-controlled trial and would like to publish the results and conclusions later. If Qishe Pill can alleviate
neck pain without adverse effects, it may be a unique strategy for the treatment of cervical radiculopathy.
Trial registration: This study is registered at ClinicalTrials.gov, NCT01274936
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Table 1 Standard formula (Capsule ingredients)*
Chinese name Pharmaceutical name Powered herb,%
Huang Qi Radix Astragali 28%(13 g)
She Xiang Muscone 0.06%(0.03 g)
Chuan Xiong Szechuan Lovage Rhizome 26%(12 g)
Fang Ji Radix Stephaniae Tetrandrae 19%(9 g)
Qing Feng Teng Ovientvine 26%(12 g)
Niu Huang Calculus Bovis Artifactus 0.6%(0.3 g)
*Pharmaceutical Terminology from Hsu [7].
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Cervical radiculopathy is a distinct consideration in the
evaluation of any patients who have neck pain and may
be defined simply as an abnormality of a nerve root,
which originates in the cervical spine [1]. The typical
cervical radiculopathy patient presents neck and arm
discomfort of insidious onset. The discomfort can range
from a dull ache to a severe burning pain. Typically, pain is
referred to the medial border of the scapula, and the pa-
tient’s chief complaint is shoulder pain. As the radiculopathy
progresses, the pain radiates to the upper or lower arm and
into the hand, along the sensory distribution of the nerve
root that is involved. The initial approach to the manage-
ment of cervical spondylopathic radiculopathy is nearly the
same as that of non-specific neck or back pain that can be
found in most patients. Conservative treatments include
non-steroidal anti-inflammatory drugs, narcotics, muscle re-
laxants, physical therapy, and transcutaneous electrical nerve
stimulation. The main objectives of conservative treatments
are to relieve pain and improve function and health-related
quality of life [2]. However, these treatments for cervical
radiculopathy are limited by their modest effectiveness [2].
Surgical treatment for cervical disc disease is indicated
when symptoms are refractory to conservative treatments
and neurological symptoms are progressive [3]. In terms
of pharmacotherapy, there is generally no randomized,
placebo-controlled trial available comparing standard
non-surgical treatment [4]. Therefore, care plans should
be designed based principally on accumulated experience,
locally available services, and patient preferences. Treat-
ment plans are developed to alleviate pain, improve func-
tion, and prevent recurrence [2].
As a complementary and alternative medicine, herbal
medicines have the potential to avoid the adverse effects
of medications and surgery [4]. Natural substances, in-
cluding herbal medicines, have been used to promote
healing and alleviate neck pain in western countries [5].
Previous studies have demonstrated that some active
substances in herbal medicine can promote Qi flow and
blood circulation to alleviate pain.
A number of studies on the effects of the Chinese
herbal medicine on cervical radiculopathy have been
proposed, but useful empirical research is insufficient.
For chronic neck pain, with or without radicular symp-
toms, there is low quality evidence suggesting that herbal
medicine is more effective than placebo for pain relief as
measured at the end of the treatment [6]. Moreover, the
size of the studies has been small and the effect was mea-
sured only in the short-term. Further research is very
likely to change both the effect size and our confidence in
the results. There is a need for randomized-controlled tri-
als (RCTs) with adequate numbers of participants that ad-
dress long-term efficacy of herbal medicines compared to
placebo.Using a well-designed clinical trial, we will survey the
efficacy of concurrent use of this remedy in relieving
neck pain. Therefore, the present study is designed to
examine efficacy and safety of Qishe Pill, a traditional
Chinese herbal medicine (TCM) compound, on neck pain
in cervical spondylopathic radiculopathy in a randomized,
double-blind, placebo-controlled trial. Results of this study
will provide evidence regarding the value of Qishe Pill as
an intervention to alleviate neck pain caused by cervical
radiculopathy.
Details of intervention
Qishe Pill is composed of processed Radix Astragali,
Muscone, Szechuan Lovage Rhizome, Radix Stephaniae
Tetrandrae, Ovientvine, and Calculus Bovis Artifactus
(Table 1) [7].
Qishe Pill is a thin 0.15 g film-coated pill; removal of
the film reveals alight brown to brown colour. The pill
has a slight odor and tastes bitter. The dosage is 25 pills,
twice daily, with a total daily dosage of 7.5 g, which is in
the dosage range defined by the National Center for
Complementary and Alternative Medicine: Astragalus
mongholicus 9–30 g; Rhizoma ligustici wallichii 3–9 g;
Radix Stephaniae Tetrandrae 4.5–9 g; Caulis Sinomenii
6–12 g; Muscone 0.03–0.1 g; Calculus Bovis Artifactus
0.15– 0.35 g.
The production process of Qishe Pill: (1) Volatile oil
is extracted from Rhizoma ligustici wallichii. (2) The
remaining drugs forma decoction is mixed with astrag-
alus membranaceus soaked for 30 minutes and sim-
mered in 10 times the amount of water, twice, for 2
hours each time. (3) The decoction is then vacuum
filtrated to a concentration of relative density 1.24-1.26
(70°C). Ethanol is mixed into the concentrated decoc-
tion to reach 70% alcohol content. (4) After standing,
filtering, and concentrating with recovery of ethanol,
the decoction is crushed into a fine powder after vac-
uum drying. (5) In the reagent of 14 times the amount
of 70% ethanol, Radix Stephaniae Tetrandrae and
Caulis Sinomeniiare is extracted with the circumfluent
alcohol three times, once 2 hour. (6) Volatile oil of
Rhizoma ligustici wallichii is mixed with 4 times the
amount of β-cyclodextrin and then dried in vacuum.
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This clinical trial is a multi-center, randomized, double-
blind, placebo-controlled design. Participants will be en-
rolled by clinic recruitment at five hospital sites (Longhua
Hospital, Shanghai University of TCM; Huadong Hospital,
Fudan University; Affiliated Hospital of Changchun Uni-
versity of TCM; TCM Hospital of Gansu province; and
TCM Hospital of Suzhou city). Participants will be
recruited in equal numbers (n=48) from each of the five
sites.
Ethical issues
This study has been approved by the Institutional Re-
view Board of Longhua Hospital, Shanghai University of
TCM on November 30th 2011 (No: 2011LCSY031). All
study participants will sign the written informed consent
prior to participation. All patients will receive written
and oral reassurance regarding the typical benign course
of the symptoms. We will explain that placebo and treat-
ment with Qishe Pill might be equally effective interven-
tions. Patients in all treatment groups will be allowed to
use painkillers when necessary. In general, paracetamol is
selected with or without a non-steroidal anti-inflammatory
drug. Patients will be asked to note their drug use, includ-
ing over-the-counter analgesics, in a specially designed
diary during the first four weeks following randomization.
Patient population and recruitment procedure
All participants will be selected from the general out-
patient clinic offive hospital sites, where the patients
willbe diagnosed with cervical radiculopathy confirmed
by a neurologist, and then diagnosed based upon clinical
manifestations (pain along the cutaneous distribution of
one or more cervical roots, which may include weakness
and hyporeflexia), physical examination, and imaging [4].
Inclusion criteria are age between 18 and 65 years,
pain or stiffness in the neck for at least 2 weeks, neck
symptoms reproducible during physical examination,
neck pain on neck disability index (NDI) of 18 or more,
and radiation of arm pain distal to the elbow, plus at
least one of provocation of neck or arm pain by neck
movements, Brachial plexus traction test, foraminal
compression test, or foraminal separation test, sensory
changes in one or more adjacent dermatomes, or muscle
weakness in one or more adjacent myotomes. Furtherinclusion prerequisites are willingness for treatment and
to adhere to measurement regimens, no involvement in
litigation, and written informed consent.
Excluded criteria are patients whose history, signs, and
symptoms suggested a potential non-benign cause (in-
cluding previous neck surgery) or evidence of a specific
pathologic condition, such as malignancy, neurologic
disease, fracture, herniated disc, or systemic rheumatic
disease, clinical signs of spinal cord compression, previous
neck trauma or treatment with surgery, obvious vertigo,
pregnant women, lactating women, currently participating
in other clinical trials, accompanied with hepatic, renal,
hematopoietic system, endocrine system, cardiovascular,
nervous system, primary and other serious diseases (serum
ALT, AST, ALP, TBIL, DBIL, Cr or BUN more than two-
fold than the upper limit of reference value), tuberculosis,
vertebral deformities, cancer and mental illness, and insuf-
ficient understanding of the Chinese language, and/or have
been treated with physical therapy or manual therapy for
neck pain during the previous 2 weeks.
Patients with concurrent headaches, non-radicular
pain in the upper extremities, and low back pain will not
be excluded, but neck pain has to be the main symptom
for all patients [8].
Patients will be recruited from May 2012 to Oct 2013
from the five sites in China. The review board at each insti-
tution approved the protocol. The study is organized and
coordinated by Longhua Hospital, Shanghai University of
TCM in Shanghai, China.
This study is to be conducted according to the protec-
tion of patients, as outlined in the Declaration of Helsinki,
and approved by the appropriate Institutional Review
Boards. Each participant will sign the written informed
consent before undergoing any examination or study pro-
cedure, in compliance with Good Clinical Practice. Pa-
tients who initially meet these eligibility criteria are then
to complete the additional baseline testing and will be ran-
domized into either the treatment or the control group.
An independent steering committee will oversee the
study.
Interventions
At randomization, patients will be assigned to receive
Qishe Pill (or matching placebo) at 3.75 g twice per day.
In this study, the same outer packing will be used for
both Qishe Pill and the matching placebo. Therefore,
the treating physicians, participants and investigators
will be blinded to treatment assignment. The Qishe Pill
and matching placebo used in the trial are both
manufactured and provided by a pharmaceutical com-
pany that meets the requirements of Good Manufac-
turing Practice. All significant medicine information,
including ingredient composition, heavy metals, etc., is
provided by the same company.
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VAS scores Yes Yes Yes Yes Yes Yes
NDI scores Yes Yes Yes Yes Yes













ECG: Electrocardiogram; VAS: Visual analogue scale; NDI: Neck disability index: SF-36:
The MOS item short from health survey.
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each visit, data will be collected on the outcome
events, compliance and adverse reactions leading to a
discontinuation of study medications. All primary
and secondary events will be documented and be
centrally adjudicated with the use of standardized
definitions.
Randomization and allocation
Treatment allocation occurs when the study participant
meets the inclusion criteria and signs the informed con-
sent form. All participating patients will be randomized
using a computerized block randomization schedule with
a multiple block size of four; 240 patients will be randomly
generated and kept in sequentially numbered opaque
envelopes. All of the Qishe Pill and placebo provided
by the pharmaceutical company will be numbered with
a label according to the randomization schedule. When
researchers administer the intervention medicine (Qishe
Pill or matching placebo), these should be administered
according to the randomized number. Randomization and
uncovering must be conducted by a statistician team as a
third party. As a result, researchers and patients are totally
blinded to treatment allocation; the only un-blinded indi-
vidual is the statistician responsible for the randomization
process. The treatment assignments are balanced within
each block.
Outcome measurements
The primary study outcome is pain severity (measured
with a visual analogue scale (VAS)). Secondary outcomes
are a composite of functional status (measured by NDI),
patient satisfaction, and adverse events as reported in
the trial. The VAS measures the amount of pain, which
is a pain score ranging from 0 (no pain) to 100 mm (very
severe pain) [9]. Operationally, the VAS score is
displayed as a horizontal line, 100 mm in length, with
word descriptors anchored at each end. The patient
marks on the line the point that they feel represents
their perception of their current pain. The VAS score is
then determined by measuring in millimeters from the
left hand end of the line to the point that the patient
marks. The VAS score and NDI will be measured at all
the measurement points (baseline, 2 and 4 weeks of
treatment duration, and 2 and 5 months of follow-up
duration).
Study schedule
The measurements that need to be performed at each
visit are listed in Table 2.
Assessment of adverse events
All subjects are to be questioned regarding adverse events
during treatment at each visit; all reported adverse eventswill be analyzed in spite of the investigators’ assessments
of causality and will be categorized according to the
Medical Dictionary for Regulatory Activities (MedDRA,
Version 8.1J).
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We calculated the sample size for this two arm trial on
the basis of the comparison treatment (Qishe Pill) versus
placebo, with equal allocation in the treatment arms and
five repeated measurements (at entry, at 2 and 4 weeks’
treatment, and at 2 and 5 months’ follow-up), with an
estimated correlation coefficient of the measurements of
ρ=0.8 and a difference in the mean value of the VAS for
neck pain of 12 mm, as a clinical relevant difference with
an estimated standard deviation in each treatment group
of 25 mm [10]. As neck pain is the main complaint in
cervical radiculopathy, we chose this outcome to calcu-
late the sample size. Under the setting of alpha = 0.05
and power = 90%, the calculated sample size of each
group is around 96. Considering 20% loss to follow-up,
the total sample size needed to detect this difference at a
5% level of significance with a power of 90% is 240
patients.Statistical analysis
The data will be collected and analyzed according to the
intention-to-treat principle. Standard statistical techniques
will be used to describe characteristics of patients in both
groups. We will compare baseline characteristics in both
groups and if incomparability appears, we will perform
the secondary analysis, adjusting for differences. The pri-
mary outcome, amount of pain, will be compared between
both groups using survival analysis and analysis of vari-
ance for repeated measures. If adjustment for possible
baseline incomparability is needed, analysis of covariance
will be performed. We will use multivariate analysis to do
retrospective analysis with the baseline data of the effect-
ive cases and ineffective cases in the treatment group. Dif-
ferences in the baseline data will be used to optimize the
inclusion criteria. We will do subgroup analysis based on
severity of pain (VAS=70 mm) and use of analgesics.Discussion
Cervical radiculopathy is a significant public health prob-
lem worldwide, accounting for 60% to 70% of all cases of
cervical spondylopathy; it is generally believed that most
symptoms can be cured or relieved by non-surgical treat-
ment [11]. The chief symptom of cervical radiculopathy is
neck pain, which usually originates from a variety of non-
specific musculoskeletal causes, including direct trauma,
progressive structural changes with or without associated
systemic disease (e.g., rheumatoid arthritis), degenerative
conditions, and chronic stress or strain injury [12,13]. A
Canadian-based cohort reported that, although cervical
spondylopathic radiculopathy is less common among the
annual incidence of neck pain (14.6%), a systematic ap-
proach to its evaluation when encountered is no less im-
portant [13]. Therefore, those considerations are uniqueto cervical radiculopathy in the assessment of patients
who have neck pain and the treatment of neck pain relief.
Analgesic and nutritive nerve medicine have consid-
erable effects on neck pain. Analgesics, such as aspirin,
seem to be relatively secure, but it is reported that
gastrointestinal reactions often appear [14]. Mecobalamin,
a neuropathy drug, can relieve neck pain by means of
stimulating the inhibition of nerve degeneration and im-
proving the excitability of nerve fibers [15]. However, it
seems to be too late to cure oncenerve degeneration
occurs.
Qishe Pill provides specific benefits for “Qi and Blood”,
terms in TCM, which can profit and activate blood circu-
lation. Using the model animal pathology comprehensive
validation, other effects have been found that indicate in-
volvement in inhibition of disc inflammation factors and
delayed disc cell apoptosis [8]. According to modern re-
search and preparation standards, Qishe Pill was devel-
oped to improve the various symptoms of cervical
radiculopathy, especially for neck pain.
Qishe Pill is composed of processed Radix Astragali,
Muscone, Szechuan Lovage Rhizome, Radix Stephaniae
Tetrandrae, Ovientvine, and Calculus Bovis Artifactus.
Based upon the theory of TCM prescription, there is a
leading, coordinating, auxiliary, and guiding effect in the
remedy components. In Qishe Pill, Radix Astragali and
Szechuan Lovage Rhizome have leading effects, Musconehas
a coordinating effect, Radix Stephaniae Tetrandrae and
Ovientvinehave auxiliary effects, and Calculus Bovis
Artifactushas guiding effects. Each component of Qishe
Pill is thought to be beneficial to neck pain patients.
The ability of AS-IV, which can be found in Radix
Astragali to inhibit the NF-qB pathway, might be one
underlying mechanism contributing to its anti-inflammatory
potential in vivo [16]. The Szechuan Lovage Rhizome extract
has been found to have the ability to inhibit platelet surface
activity and platelet aggregation [17]. The Radix Stephaniae
Tetrandrae exerts anti-inflammatory effects by interfering
with ROS production and Ca2+ influx through G protein
modulation to prevent Mac-1 up-regulation in neutrophil
activation [18]. Ovientvineis used in TCM to treat pain,
arthritis, etc., and its extract could inhibit synthesis
and release of local PGE [19]. Calculus Bovis Artifactus
could decrease the malondialdehydecontent in inflam-
matory exudates induced by carrageen an in rats [20]. Pre-
treatment with muscone inhibited the IL-1beta-induced
phosphorylation of extracellular signal-regulated ki-
nases 1/2 and c-Jun N-terminal kinase in a dose-
dependent manner, and the expression of prostaglandin E2,
6-keto-prostaglandin F1alpha, IL-1beta, and tumor necrosis
factor alpha, and recovered the structural distortion of the
degenerative disc. Musconeis a promising agent in the treat-
ment of intervertebral disc degeneration through its
anti-inflammatory effects [21]. Qishe Pill prevents
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posture [22].
Outcome measures assessing patients with neck pain
are used widely in research and in clinical settings to es-
tablish baselines, to evaluate the effect of an intervention,
and to motivate patients to evaluate their treatment. Gen-
erally, the VAS measurements have been found to be both
valid and reliable. In many studies, the VAS has been
shown to be the easiest to use and is considered to provide
the most reliable measurements of pain intensity; it is
therefore used as the criterion standard against new rating
methods [23]. Similarly, the NDI, a neck-specific question-
naire, has been cited in the literature as the criterion
standard for many other questionnaires and is the most
valid of the tools reported [24-27]. Furthermore, the NDI
discriminates between those who improved or deterio-
rated and, as expected, does not detect change in score in
those who remained stable [28]. Therefore, for the self-
effectiveness assessment, we selected the VAS for self-
assessment of pain and NDI for self-assessment of
function.
We intend to conduct this well designed RCT to in-
vestigate both the efficacy and safety of Qishe Pill in pa-
tients with neck pain, and consider that conscientiously
performed studies and positive outcomes can benefit pa-
tients with neck pain. If this study demonstrates the effi-
cacy and safety of Qishe Pill in significant strides, it will
contribute to a useful clinical therapy for relieving neck
pain in cervical radiculopathy.
Trial status
Participant recruitment began in September 2012 and fin-
ished in three sites (Longhua Hospital, Shanghai University
of TCM; Affiliated Hospital of Changchun University of
TCM; TCM Hospital of Gansu province); while 28 partici-
pants have been enrolled in Huadong Hospital, Fudan
University and 30 in TCM Hospital of Suzhou city.
We periodically organized meetings to give partici-
pants feedback(recruitment or follow-up) on progress
and conducted regular quality controls of all the trial
sites by means of telephone conversations with every
participant to verify the case report form. Data collection
will be recorded in an eCRF system during the clinical
trial.
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